Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.

Journal Article (Journal Article)

To better define the role of B cells in the control of pathogenic simian immunodeficiency virus (SIV) replication, six rhesus monkeys were depleted of B cells by intravenous infusion of rituximab (anti-CD20) 28 days and 7 days before intravaginal SIVmac239 inoculation and every 21 days thereafter until AIDS developed. Although the blood and tissues were similarly depleted of B cells, anti-SIV immunoglobulin G (IgG) antibody responses were completely blocked in only three of the six animals. In all six animals, levels of viral RNA (vRNA) in plasma peaked at 2 weeks and declined by 4 weeks postinoculation (PI). However, the three animals prevented from making an anti-SIV antibody response had significantly higher plasma vRNA levels through 12 weeks PI (P = 0.012). The remaining three B-cell-depleted animals made moderate anti-SIV IgG antibody responses, maintained moderate plasma SIV loads, and showed an expected rate of disease progression, surviving to 24 weeks PI without developing AIDS. In contrast, all three of the B-cell-depleted animals prevented from making anti-SIV IgG responses developed AIDS by 16 weeks PI (P = 0.0001). These observations indicate that antiviral antibody responses are critical in maintaining effective control of SIV replication at early time points postinfection.

Full Text

Duke Authors

Cited Authors

  • Miller, CJ; Genescà, M; Abel, K; Montefiori, D; Forthal, D; Bost, K; Li, J; Favre, D; McCune, JM

Published Date

  • May 2007

Published In

Volume / Issue

  • 81 / 10

Start / End Page

  • 5024 - 5035

PubMed ID

  • 17329327

Pubmed Central ID

  • PMC1900210

International Standard Serial Number (ISSN)

  • 0022-538X

Digital Object Identifier (DOI)

  • 10.1128/JVI.02444-06


  • eng

Conference Location

  • United States